VanEck Pharmaceutical ETF
86 hedge funds and large institutions have $427M invested in VanEck Pharmaceutical ETF in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 13 closing their positions.
1,704% more call options, than puts
Call options by funds: $7.4M | Put options by funds: $410K
25% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 24
23% more capital invested
Capital invested by funds: $347M → $427M (+$80.6M)
12.76% more ownership
Funds ownership: 64.52% → 77.28% (+13%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less funds holding
Funds holding: 91 → 86 (-5)
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$128M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$4.53M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$3.72M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.46M |
| 5 |
LPL Financial
San Diego,
California
|
+$2.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$6.13M |
| 2 |
Jane Street
New York
|
-$2.69M |
| 3 |
M&T Bank
Buffalo,
New York
|
-$2.2M |
| 4 |
LJAC
L.J. Altfest & Co
New York
|
-$836K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$799K |
PPH Hedge Fund Activity: Q3 2022 in Review
86 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q3 2022, worth a combined $427M — up 23% from $347M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of PPH and 8 opened new positions — a net loss of 5 holders — while 24 trimmed existing stakes and 30 added.
The largest buyer was Goldman Sachs, adding an estimated $128M. The largest seller was Morgan Stanley, cutting an estimated $6.13M.
- 86 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q3 2022, down from 91 in Q2 2022.
- Funds reported $427M of VanEck Pharmaceutical ETF stock for Q3 2022, up 23% quarter-over-quarter.
- 8 funds opened new VanEck Pharmaceutical ETF positions in Q3 2022 and 13 closed out, a net change of -5 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q3 2022 was Goldman Sachs, an estimated $128M added.
- The largest VanEck Pharmaceutical ETF seller in Q3 2022 was Morgan Stanley, an estimated $6.13M sold.
Based on aggregated 13F filings for Q3 2022.